Vol 50, No 3 (2012)
Original paper
Published online: 2012-10-08
Antitumor effect of murine dendritic and tumor cells transduced with IL-2 gene
DOI: 10.5603/FHC.2012.0056
Folia Histochem Cytobiol 2012;50(3):414-419.
Abstract
Interleukin (IL-) 2 acts on a number of types of immune cells promoting their effector functions. To replace
systemic administration of recombinant form of this cytokine, various genetically modified cells have been used in
different preclinical models for tumor growth inhibition. In this study, dendritic or tumor cells transduced with retroviral
vector carrying IL-2 gene (JAWS II/IL-2, X63/IL-2, MC38/IL-2 cells) alone or combined with tumor antigenstimulated
dendritic cells (JAWS II/TAg) were exploited to treat colon carcinoma MC38-bearing mice. After the
peritumoral injection of vaccine cells, the tumor growth delay and the increase in the number of tumor infiltrating
CD4+ and CD8+ T lymphocytes were noted. A considerable increase in CD4+ cell influx into tumor tissue was observed
when JAWS II/IL-2 cells or JAWS II/TAg with syngeneic MC38/IL-2 cells were applied. The increase in
intensity of CD8+ cell infiltration was associated with immune reaction triggered by the same combination of applied
cells or JAWS II/TAg with allogeneic X63/IL-2 cells. The effect observed in vivo was accompanied by MC38/0 cell
specific cytotoxic activity of spleen cells in vitro. Thus, the application of vaccines, including IL-2-secreting cells of
various origins, was able to induce different antitumor responses polarized by exogenous IL-2 and the encountered
tumor antigen.
systemic administration of recombinant form of this cytokine, various genetically modified cells have been used in
different preclinical models for tumor growth inhibition. In this study, dendritic or tumor cells transduced with retroviral
vector carrying IL-2 gene (JAWS II/IL-2, X63/IL-2, MC38/IL-2 cells) alone or combined with tumor antigenstimulated
dendritic cells (JAWS II/TAg) were exploited to treat colon carcinoma MC38-bearing mice. After the
peritumoral injection of vaccine cells, the tumor growth delay and the increase in the number of tumor infiltrating
CD4+ and CD8+ T lymphocytes were noted. A considerable increase in CD4+ cell influx into tumor tissue was observed
when JAWS II/IL-2 cells or JAWS II/TAg with syngeneic MC38/IL-2 cells were applied. The increase in
intensity of CD8+ cell infiltration was associated with immune reaction triggered by the same combination of applied
cells or JAWS II/TAg with allogeneic X63/IL-2 cells. The effect observed in vivo was accompanied by MC38/0 cell
specific cytotoxic activity of spleen cells in vitro. Thus, the application of vaccines, including IL-2-secreting cells of
various origins, was able to induce different antitumor responses polarized by exogenous IL-2 and the encountered
tumor antigen.
